Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
55.51 USD | +2.04% |
|
+2.45% | -33.51% |
Jun. 24 | JPMorgan Cuts Price Target on Cytokinetics to $65 From $77, Maintains Overweight Rating | MT |
Jun. 17 | Cytokinetics Insider Sold Shares Worth $262,750, According to a Recent SEC Filing | MT |
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-33.51% | 6.45B | |
+16.61% | 122B | |
+17.75% | 112B | |
+17.23% | 25.91B | |
-24.11% | 19.33B | |
-18.56% | 16.17B | |
-18.47% | 15.56B | |
-47.75% | 14.65B | |
+57.35% | 14.34B | |
+5.62% | 14B |
- Stock Market
- Equities
- CYTK Stock
- News Cytokinetics, Incorporated
- Transcript : Cytokinetics, Incorporated - Shareholder/Analyst Call